[M T]

While supporting caution in viewing some suggestive (but not even preliminary) evidence, I expect all of us are hoping that the optimistic hopes wind up being right.

There's gonna be a run on it so that even if it works ( my understanding is the literature is preliminary and it is not a miracle cure but may mildly improve outcomes for some patients), no one will get it because the supply has been bought up by people who don't need it.

I'm not sure I'd even call it "preliminary".  This site references the outcome of 6 patients a basis.  That's appropriate for calling for a study.  I wouldn't have worded this as they did.

A recent controlled clinical study conducted by Didier Raoult M.D/Ph.D, et. al in France has shown that 100% patients that received a combination of HCQ and Azithromycin tested negative and were virologically cured within 6 days of treatment.

Following that "controlled clinical study" link, gives this

Among hydroxychloroquine-treated patients six patients received azithromycin (500mg on day1
followed by 250mg per day, the next four days) to prevent bacterial super-infection under
daily electrocardiogram control.

The HCQ data also seems to be a bit cherry-picked in that a significant number of the original set
that had bad outcomes were excluded, perhaps reasonably so. (Here I openly admit to
cherry-picking the outcomes that were negative.)  I would suggest that this means that some of
the tougher cases were in fact removed from the study, leading to better numbers than might be real.

We enrolled 36 out of 42 patients meeting the inclusion criteria in this study that had at least
six days of follow-up at the time of the present analysis. A total of 26 patients received
hydroxychloroquine and 16 were control patients. Six hydroxychloroquine-treated patients
were lost in follow-up during the survey because of early cessation of treatment. Reasons are
as follows: three patients were transferred to intensive care unit, including one transferred on
day2 post-inclusion who was PCR-positive on day1, one transferred on day3 post-inclusion
who was PCR-positive on days1-2 and one transferred on day4 post-inclusion who was PCR-
positive on day1 and day3; one patient died on day3 post inclusion and was PCR-negative on
day2; one patient decided to leave the hospital on day3 post-inclusion and was PCR-negative
on days1-2; finally, one patient stopped the treatment on day3 post-inclusion because of
nausea and was PCR-positive on days1-2-3.

[M T]

While supporting caution in viewing some suggestive (but not even preliminary) evidence, I expect all of us are hoping that the optimistic hopes wind up being right.

There's gonna be a run on it so that even if it works ( my understanding is the literature is preliminary and it is not a miracle cure but may mildly improve outcomes for some patients), no one will get it because the supply has been bought up by people who don't need it.

I'm not sure I'd even call it "preliminary".  This site references the outcome of 6 patients a basis.  That's appropriate for calling for a study.  I wouldn't have worded this as they did.

A recent controlled clinical study conducted by Didier Raoult M.D/Ph.D, et. al in France has shown that 100% patients that received a combination of HCQ and Azithromycin tested negative and were virologically cured within 6 days of treatment.

Following that "controlled clinical study" link, gives this

Among hydroxychloroquine-treated patients six patients received azithromycin (500mg on day1
followed by 250mg per day, the next four days) to prevent bacterial super-infection under
daily electrocardiogram control.

The HCQ data also seems to be a bit cherry-picked in that a significant number of the original set
that had bad outcomes were excluded, perhaps reasonably so. (Here I openly admit to
cherry-picking the outcomes that were negative.)  I would suggest that this means that some of
the tougher cases were in fact removed from the study, leading to better numbers than might be real.

We enrolled 36 out of 42 patients meeting the inclusion criteria in this study that had at least
six days of follow-up at the time of the present analysis. A total of 26 patients received
hydroxychloroquine and 16 were control patients. Six hydroxychloroquine-treated patients
were lost in follow-up during the survey because of early cessation of treatment. Reasons are
as follows: three patients were transferred to intensive care unit, including one transferred on
day2 post-inclusion who was PCR-positive on day1, one transferred on day3 post-inclusion
who was PCR-positive on days1-2 and one transferred on day4 post-inclusion who was PCR-
positive on day1 and day3; one patient died on day3 post inclusion and was PCR-negative on
day2; one patient decided to leave the hospital on day3 post-inclusion and was PCR-negative
on days1-2; finally, one patient stopped the treatment on day3 post-inclusion because of
nausea and was PCR-positive on days1-2-3.